The Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.
Letter to the Editor
A case of stenting for acute cerebral venous sinus thrombosis in the superior sagittal sinus Naoki Matsumoto, Yoji Kuramoto, Narihide Shinoda and Yasushi Ueno
We wish to share our experience of a patient with cerebral venous and sinus thrombosis (CVST) in whom endovascular stenting resulted in a good clinical outcome as recently reported by Adachi et al. 1 A 44-year-old woman presented with headache and right arm weakness. Magnetic resonance imaging (MRI) revealed brain edema at the left temporal lobe (Figure 1(a) ). T1-weighted MRI with gadolinium demonstrated an 'empty delta sign' in the cerebral sinus ( Figure 1(b) ). Digital subtraction angiography (DSA) revealed occlusion of the superior sagittal sinus (SSS) and venous congestion in the left temporal lobe (Figure 1(c) ). We attempted thrombolysis.
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Corresponding author: Naoki Matsumoto, Department of Neurosurgery, Kyoto University Hospital, 54 Shogoinkawahara-cho, Sakyo-ku,Kyoto-shi,Kyoto 606-8507, Japan. Email: naoki@kuhp.kyoto-u.ac.jp Throughout the procedure, heparin was administered to maintain an activated clotting time of 250 to 300 seconds. A 7 French (F) guiding catheter was placed in the right internal jugular vein. We placed a microcatheter into SSS and injected 120,000 units of urokinase. However, this was totally ineffective. Subsequently, we attempted balloon angioplasty, introducing a Gateway 2.5 mm Â 3.0 mm and 3.5 mm Â 3.0 mm (Stryker, Kalamazoo, MI, USA), but this did not improve venous flow. We then placed three intracranial stents (4.5 Â 37 mm, 4.5 Â 28 mm, 4.5 Â 28 mm) (ENTERPRISE Vascular Reconstruction Device: Codman & Shurtleff, Johnson & Johnson), which restored the patency of the SSS. There was an immediate improvement in the patient's headache after recanalization. Following the intervention, the patient was given anticoagulation therapy for 3 months. Three months later, DSA demonstrated SSS patency (Figure 1(d) ). Postoperatively, she has not experienced a recurrence of CSVT for 3 years.
The standard therapy for CVST is anticoagulation therapy. However, good outcomes have been reported following thrombolytic therapy and mechanical clot disruption. Reports describe urokinase 2 as thrombolytic therapy, and percutaneous transluminal angioplasty balloon 3 as angioplasty.
In our case, immediate intravascular treatment reduced hemorrhagic risk and prevented a worsening of the patient's clinical symptoms, which improved after recanalization. Endovascular stenting was successful, in our case, in treating CVST, suggesting that stenting can be considered as a viable treatment option for CVST.
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